23andMe, Inc.☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

23andMe, Inc. is one of 21302 Other Technology companies tracked from Sunnyvale. By capital raised it ranks among the largest (ahead of 100% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

23andMe is a saliva-based DNA service. We provide genetic reports on your ancestry, family history and help you connect with your DNA relatives.

23andMe is a saliva-based DNA service. We provide genetic reports on your ancestry, family history and help you connect with your DNA relatives. Exclusive Offer: Buy one kit, get 20% OFF each additional kit. See cart for details. Buy now Understand the larger context of where you come from, breaking down your ancestry to the 0.1%. It's the most comprehensive genetic breakdown on the market, helping you gain a more complete portrait of yourself. Discover where in the world your DNA is from across 4,500+ locations - in some cases, down to the county level. Time hop to gain a clearer picture of where you came from, where your ancestors lived and when they lived there. From close family members to distant branches, you'll be amazed by the myriad of people you could be connected to. Open your world to DNA relatives, old and new. There is no advanced science that comes before your protection. Read more about our enhanced measures designed to keep your data safe, in any scenario. 23andMe has rigorous standards that ensure high-quality results. Our team of scientists and medical experts use a robust process to develop genetic reports for our customers. Here are specific examples: After you

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Round size and date are reported; the stage label is inferred from round size (latest is Series D+ — a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the technology sector profile. Directional, not a quoted figure.

Benchmarked against 21302 companies in Other Technology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 100% of sector peers (real $). Modeled value above 98% of peers (estimate).

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #84 of 105.

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Series B$27.8M2009-02-10
   • First recorded raise — entered as Series B.
   • 5 investors on this round.
2. Series B$27.8M2009-04-16
   • Came back fast: 2 mo vs the ~13 mo sector norm.
   • Round roughly the size of the prior one.
   • 5 investors on this round.
3. Series A$11.0M2009-04-16
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round 2.5× smaller than the prior — bridge or down round.
   • 1 investor on this round.
4. Series B$22.2M2010-11-05
   • Raised 19 mo later, in step with the ~13 mo sector norm.
   • Round 2.0× larger than the prior — scaling up.
   • 8 investors on this round.
5. Series C$57.9M2012-12-10
   • Raised again after 25 mo — slower than the ~13 mo sector norm.
   • Round 2.6× larger than the prior — scaling up.
   • 6 investors on this round.
6. Series C$79.1M2015-06-18
   • Raised again after 30 mo — slower than the ~13 mo sector norm.
   • Round 1.4× larger than the prior — scaling up.
   • Switched to Rule 506(b) (was Rule 06).
   • 15 investors on this round.
7. Series D+$250.0M2017-08-31
   • Raised again after 26 mo — slower than the ~13 mo sector norm.
   • Round 3.2× larger than the prior — scaling up.
   • 31 investors on this round.
8. Series D+$300.0M2018-07-24
   • Raised 11 mo later, in step with the ~13 mo sector norm.
   • Round roughly the size of the prior one.
   • 1 investor on this round.
9. Series D+$82.5M2020-12-09
   • Raised again after 29 mo — slower than the ~13 mo sector norm.
   • Round 3.6× smaller than the prior — bridge or down round.
   • 23 investors on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

23andMe, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where 23andMe, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at 23andMe, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.